Inadequate reporting of trials compromises the applicability of systematic reviews

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 3, 2009, Pages 323-330

  Gartlehner, Gerald ^a   Thieda, Patricia ^b   Hansen, Richard A ^b,e   Morgan, Laura C ^b   Shumate, Janelle A ^c   Nissman, Daniel B ^d  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

Effectiveness; Efficacy; Explanatory studies; Methods study; Pragmatic studies; Systematic reviews

Indexed keywords

ADVERSE EVENTS; ALZHEIMER'S; CONTROLLED TRIAL; IMMUNE MODULATORS; POLICY DECISIONS; SAMPLE SIZES; STUDY DESIGN; SYSTEMATIC REVIEW;

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; IMMUNOMODULATING AGENT; MEMANTINE;

ALZHEIMER DISEASE; ANKYLOSING SPONDYLITIS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CROHN DISEASE; DATA BASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR DEPRESSION; MEDICAL INFORMATION; METHODOLOGY; POPULATION; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; SAMPLE SIZE; SYSTEMATIC REVIEW; CLINICAL TRIAL; DOCUMENTATION; PUBLISHING; STANDARD;

CLINICAL TRIALS AS TOPIC; DOCUMENTATION; PUBLISHING; QUESTIONNAIRES;

EID: 70350447491     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990122     Document Type: Review

References (31)

1. Agency for Healthcare Research and Quality (AHRQ). http:// effectivehealthcare.ahrq.gov/aboutUs/index.cfm (accessed November 15, 2008).
2. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-694. (Pubitemid 32322245)
3. Atkins D. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs. Med Care. 2007;45(Suppl 2):S16-S22.
4. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457-2465.
5. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomized controlled trials. BMJ. 2006;332:969-971.
6. Ethgen M, Boutron I, Baron G, et al. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med. 2005;143:20-25.
7. Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4:104-108.
8. Gartlehner G, Hansen RA, Kahwati L, et al. Drug class review on second generation antidepressants. http://www.ohsu.edu/ ohsuedu/research/policycenter/ customcf/derp/product/AD2-Final-Report-%20Update%203.pdf (accessed November 15, 2008).
9. Gartlehner G, Hansen RA, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59:1040-1048.
10. Gartlehner G, Hansen RA, Thieda P, et al. Drug class review on targeted immune modulators. http://www.ohsu.edu/ ohsuedu/research/policycenter/customcf/ derp/product/TIM-Final-Report-Update%2012.pdf (accessed November 15, 2008).
11. Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol. 2003;3:28.
12. Gross CP, Mallory R, Heiat A, et al. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med. 2002;137:10-16.
13. Hansen RA, Gartlehner G, Kaufer DJ, et al. Drug class review on Alzheimer's drugs. http://www.ohsu.edu/ohsuedu/ research / policycenter / customcf / derp / product /ALZ-Final-Report-Update%201.pdf (accessed November 15, 2008).
14. Hansen RA, Gartlehner G, Lohr KN, et al. Drug class review on inhaled corticosteroids. http://www.ohsu.edu/ohsuedu/ research / policycenter / customcf / derp / product / ICS-Final-Report-Update%201.pdf (accessed November 15, 2008).
15. Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ. 1999;319:652-653.
16. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385-396.
17. Hewitt C, Hahn S, Torgerson DJ, et al. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ. 2005;330:1057-1058.
18. Huwiler-Muntener K, Juni P, Junker C, et al. Quality of reporting of randomized trials as a measure of methodological quality. JAMA. 2002;287:2801-2804.
19. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-788.
20. MacRae KD. Pragmatic versus explanatory trials. Int J Technol Assess Health Care. 1989;5:333-339.
21. Malmivaara A, Koes BW, Bouter LM, et al. Applicability and clinical relevance of results in randomized controlled trials: the Cochrane review on exercise therapy for low back pain as an example. Spine. 2006;31:1405-1409.
22. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Onkologie. 2000;23:597-602. (Pubitemid 32046061)
23. Moher D, Schulz KF, Altman D. The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY). 2005;1:40-45.
24. Mullner M, Matthews H, Altman DG. Reporting on statistical methods to adjust for confounding: a cross-sectional survey. Ann Intern Med. 2002;136:122-126.
25. Mulrow CD. Rationale for systematic reviews. BMJ. 1994;309:597-599.
26. Oregon Health and Science University (OHSU). http://www.ohsu.edu/ drugeffectiveness/description/index.htm (accessed November 15, 2008).
27. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Med J Aust. 2006;185:263-267.
28. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637-648.
29. Slutsky J, Atkins D, Chang S, et al. Comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2008 [Epub ahead of print].
30. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003;48:313-318.
31. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390.